The Korean Society of by The Pennsylvania State University CiteSeerX Archives
JNM Journal of Neurogastroenterology and Motility Review
2014 The Korean Society of Neurogastroenterology and Motility
J Neurogastroenterol Motil,  Vol. 20  No. 1   January,  2014
www.jnmjournal.org
J Neurogastroenterol Motil,  Vol. 20  No. 1   January,  2014
pISSN: 2093-0879   eISSN: 2093-0887
http://dx.doi.org/10.5056/jnm.2014.20.1.31
31
Methanogens, Methane and Gastrointestinal 
Motility
Konstantinos Triantafyllou,1,2 Christopher Chang1 and Mark Pimentel1*
1GI Motility Program, Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; and 2Hepatogastroenterology Unit, 
Second Department of Internal Medicine and Research Institute, Attikon University General Hospital, Medical School, Athens University, Athens, 
Greece
Anaerobic fermentation of the undigested polysaccharide fraction of carbohydrates produces hydrogen in the intestine which 
is the substrate for methane production by intestinal methanogens. Hydrogen and methane are excreted in the flatus and in 
breath giving the opportunity to indirectly measure their production using breath testing. Although methane is detected in 
30%-50% of the healthy adult population worldwide, its production has been epidemiologically and clinically associated with 
constipation related diseases, like constipation predominant irritable bowel syndrome and chronic constipation. While a causa-
tive relation is not proven yet, there is strong evidence from animal studies that methane delays intestinal transit, possibly act-
ing as a neuromuscular transmitter. This evidence is further supported by the universal finding that methane production 
(measured by breath test) is associated with delayed transit time in clinical studies. There is also preliminary evidence that anti-
biotic reduction of methanogens (as evidenced by reduced methane production) predicts the clinical response in terms of 
symptomatic improvement in patients with constipation predominant irritable bowel syndrome. However, we have not identi-
fied yet the mechanism of action of methane on intestinal motility, and since methane production does not account for all 
constipation associated cases, there is need for high quality clinical trials to examine methane as a biomarker for the diagnosis 
or as a biomarker that predicts antibiotic treatment response in patients with constipation related disorders.
(J Neurogastroenterol Motil 2014;20:31-40)
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Introduction
The composition of gases generated in the intestine shows 
both inter-individual variability and variability among the differ-
ent anatomical sites of the gastrointestinal tract. Hydrogen ( 2) 
and methane (CH4) are mostly produced in the large intestine of 
normal subjects, during the partial or full fermentation of the un-
digested polysaccharide fraction of certain carbohydrates by the 
anaerobic flora.1 However, in cases of small bowel bacterial over-
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30% 76
Breath test positivity
  (  3 hr)
36-61% 22, 30, 31
Stool culture 12% of the anaerobes 15, 16
PCR, polymerase chain reaction.
growth (SIBO), these gases are produced in the small intestine 
and can be detected using breath testing - an indirect and easy 
method to detect SIBO.2
The quantitative equilibrium of gas concentrations in the in-
testine is delicate and one gas affects the other. CH4 is produced 
using 2 and CO2 during methanogenesis performed mainly by a 
group of anaerobes called methanogens in the intestine. Metha-
nogenesis and methanogens are well known from livestock stu-
dies. Digestion of “roughage” in ruminant animals produces 
huge amounts of methane and measures have been undertaken to 
reduce cattle methane emissions either with diet modification or 
by introducing anti-menthanogen vaccination and antibiotics in 
order to control global warming and loss of energy.3 
Methane has previously been considered an inactive gas that 
it is mainly excreted in flatus, while a certain amount is excreted 
in breath.4 However, recently, methane has been associated with 
gastrointestinal disorders, mainly chronic constipation and con-
stipation predominant irritable bowel syndrome (IBS),4,5 as well 
as metabolic diseases like obesity.6
The purpose of this review is to provide comprehensive in-
sights on methanogenesis and on the association of methane with 
gastrointestinal motility. 
Methanogens
Among the numerous microorganisms that outnumber eu-
karyotic cells in human gut, methanogens are primitive “bugs” 
belonging to the Kingdom Archaea, one of the three distinct 
branches of the phylogenetic evolutionary descent; bacteria and 
eukaryota being the other two. These organisms are no longer 
considered prokaryotic organisms and share some similarities 
with the eukaryotic cells.7 They have some unique properties: live 
in strictly anaerobic conditions,8 difficult cultivation, requiring 
specific conditions and media,9 and cell wall lacking peptidogly-
can making them therefore susceptible to certain antibiotics (i.e., 
chloramphenicol and bacitracin) and resistant to many common 
others like penicillins and aminoglycosides.10 The genetic diver-
sity of methanogens in humans is limited11; only 3 phylotypes 
have been detected: Methaninobrevibacter smithii is the dominant 
methanogen in the intestine followed by Methanospaera stadmag-
nae12 whereas Methannobrevibacter oralis which is implicated in 
periodontal disease is the main archaeon in the oral cavity.13 
Using molecular techniques, other archaea inhabitants of the hu-
man intestine have been identified, however, their role in health 
and disease and their co-operation with methanogens remains still 
obscure.14 
Using either molecular12 or culture techniques,15,16 metha-
nogens account for approximately 10% of the human colon anae-
robes, whereas using modern polymerase chain reaction (PCR) 
techniques, 80% to almost 100% colonization of the human colon 
by M. smithii has been detected.17,18
There is evidence using quantitative PCR techniques that 
methanogens colonize in the human intestine early after birth. 
Methanogens were found in fecal samples of a 1 year old infant,19 
while archaeal 16S rRNA was detected even in the meconium.20 
These finding support the hypothesis that contact with the moth-
er’s vaginal and intestinal flora during vaginal delivery might be 
an important source for the colonization of the infant gut.21 
Moreover, studies in families22 and in twins23 support the hy-
pothesis that environmental factors are associated with methano-
genic flora transmission, independently of genetically predis-
position. The distribution of methanogens in human colon is as-
sociated with the consistency of the feces; in the left colon where 
stool is solid, methanogens predominate.24 Recently, M. smithii 
was found in the human duodenum accounting for almost 20% of 
all microbes in this location.25 Table 1 presents the prevalence of 
methanogenic flora using different diagnostic tests.
Methanogenesis and Methane
Methanogenesis is a unique metabolic process whereby CO2 
is reduced to CH4 using H2 produced by anaerobic bacterial fer-
mentation as an electron donor. The procedure is undertaken by 
methanogens, although certain Clostiridium and Bacteroides spe-
cies can also produce CH4.
26 Through this procedure metha-
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Table 2. Predisposing Factors for Methane Breath Test Positivity in Healthy Humans
Predisposing factor Methane detection in breath test Reference(s)




Socioeconomic status High in lower socioeconomic situations 43
Gender Higher in females than in males 22, 39-41
Age Age  3 yr: undetectable
Age 3-15 yr: increases and reached adults levels by adolescence
20, 31, 37
22, 36
Family clustering Similar levels between sibling, parents and children but not in spouses 22, 23
nogens obtain energy to survive and they reduce the gas molar 
volume in the intestine since for the production of 1 mole of CH4, 
4 H2 moles are consumed.
27 However, methanogens compete 
with sulfate reducing bacteria and acetogenic bacteria for H2, and 
the outcome of the competition is governed by factors such as the 
availability of substrates, thermodynamics and pH. As previously 
illustrated by Sahakian et al,4 acetogenesis which is not common 
in the human colon (restricted to the right colon, if present) leads 
to acetate production through the least thermodynamically favor-
able process for the consumption of 2. Therefore, it is favored 
by the absence of methanogens and acidic pH. In contrast, sul-
fide production is a more favorable thermodynamic process for 
H2 elimination but requires alkaline pH and a rare substrate 
(sulfate) in the human intestine. Due to low sulfate in human diet, 
an abundance of methanogenic flora and its substrate (CO2), 
stool neutral pH and thermodynamics make CH4 production the 
dominant process for H2 consumption by intestinal microor-
ganisms.4 However in certain occasions, such as ingestion of sul-
fate through alcoholic beverages (bear, wine and cider) or bread28 
and hypochlorhydria that can change stool pH to alkaline may 
change the equilibrium in favor for sulphate-reducing bacteria. 
Once produced, intestinal methane can be excreted either in 
the flatus or exhaled after traversing the gut mucosa and entering the 
systemic circulation without any further metabolism.22 Twenty23 to 
fifty percent29 of the methane produced is excreted in the exhaled 
breath giving the opportunity for breath testing to become an in-
direct measurement of its production in the intestine. 
Lactulose breath testing measures methane and hydrogen in 
breath samples obtained at baseline and every 15 to 20 minutes 
after 10 grams lactulose ingestion until 180 minutes or even later, 
using gas chromatography. Methane breath testing shows 2 dis-
crete patterns of the gas production after lactulose ingestion: (1) 
high baseline level and early rise in the breath methane, associated 
probably with SIBO production; and (2) late rise, corresponding 
to the arrival of lactulose at the left colon, where methanogens di-
gest it in normal humans.30
While lactulose is usually the substrate for breath testing, 
other substrates like glucose and sucrose have also been used. 
Methane breath testing positivity is variably defined in the liter-
ature depending on the substrate and the cut-off used: it ranges 
from  1 part per million (ppm) above the atmospheric concen-
tration (1.8 ppm)22,31 to  3 ppm32,33 and  10 ppm34 any time 
during the test. 
Based on early study,22 individuals are categorized as meth-
ane producers and non-producers, accounting approximately for 
the 35% and 65% of a healthy Western population, respectively. 
Surprisingly, the proportion of methane producers remained sta-
ble over 35 years between 1970 and 2005, despite increase in anti-
biotics consumption and diet modifications that occurred during 
the same period.31
An absence of methane in the breath does not mean absence 
of methanogenic flora. On the contrary, methanogens are present 
in the vast majority of the health adults’ flora, almost universally.6 
However, it seems that there is a threshold of approximately 108 
methanogens per gram dry weight of stool in order to detect the 
generated methane in breath sample35; and methane producers 
harbor 107 to 1010 methanogens per gram dry weight of stool.27
In contrast to Bond et al,22 recent studies indicate that the 
prevalence of healthy adults methane producers ranges between 
36% and 63%.30,31,36 Several factors have been associated with 
this wide range. One of them is the definition of methane posi-
tivity. While recently, methane positivity is defined based on early 
(180 minutes) breath test positivity, other studies estimate metha-
nogens prevalence using late breath testing positivity or baseline 
positivity (Table 1). 
Table 2 presents the predisposing factors for methane breath 
testing positivity in healthy humans. Geographic differences ap-
pear important with the highest prevalence in Nigeria and in 
South Africa (77% and 87%, respectively)37,38 and the lowest in 
Norway and in Minneapolis-area (34% and 35%, respective-
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ly).31,39 Female sex has been also associated with CH4 positive 
producer status in many studies,22,39-41 but not universally.31 Age 
is linked to breath methane detection; while methane is not de-
tected in breath of children aged  3 years,20,31,37 its detection 
reaches the prevalence of adults by adolescence.22,36
It has been shown that there is a family clustering of CH4 
production, being similar between siblings and in parents and 
children but not in spouses22 indicating that environmental fac-
tors are also important for methane production, similar to the 
findings of the molecular studies discussed previously.23 More 
precisely, low (9%) but existence of discordance between identi-
cal twins,22 and not so high concordance rate between mono-
zygotic twins, which was similar in dizygotic twins23 indicate a 
role for environmental factors. However, one twin study chal-
lenged this hypothesis, indicating the presence of genetically pre-
disposition as well.42
Recently, methane production status has been related with 
low socioeconomically conditions. High methane production was 
detected in children living in slum area irrespective of the pres-
ence of SIBO, suggesting that methane measurement might be 
an indicator of environment contamination.43
Methane and Disease Associations
Certain gastrointestinal diseases have been associated with 
positive methane producer status, including colon cancer. As ear-
ly as in 1977, Heins and his colleagues44 showed that the number 
of methane producers among patients with colorectal cancer oc-
cluding the left colon was double than that of the general pop-
ulation, indicating a possible relation between methane pro-
duction and colon cancer. However, following this observation 
there were only two more small studies in favor of this association 
while 10 studies failed to confirm it, as illustrated by Roccarina et 
al.5 Diverticulosis is associated with methane production35,45 and 
while diarrheal conditions like inflammatory bowel disease are 
negatively associated with methane production,29,33 there is 
strong evidence that methane is positively associated with in-
testinal motility disorders like constipation32,46 and constipation 
predominant IBS.4,33,47
Physiological Effects of Methane
Recent data48 has challenged the perception that methane and 
slowed intestinal motility just coexist or that the abundance of 
methane is secondary to impaired intestinal motility and proposed 
that there is a causative relation of methane production and intes-
tine motility disturbance. Investigators showed in a three-part 
translational and human study that: (1) intestinal methane in-
fusion through surgically created fistulae in an in vivo canine 
model significantly slowed small intestinal transit time by 59%, as 
assessed by scintigraphy; (2) exposure to methane augmented 
ileal circular muscle contractile activity in an ex vivo guinea pig 
ileum experiment; and (3) IBS methane producers had sig-
nificantly higher fasting and post-prandial motility indices, as 
well as, isolated fasting contractions during antro-duodenal man-
ometry compared to IBS H2 producers. The consistency of the 
motility findings in response to methane in the animal models and 
in human subjects provided for the first time experimental evi-
dence that methane may not be an inert intestinal gas, but it can 
intervene to the neuromuscular function of the intestinal track. 
Moreover, the results in the isolated ileum segment of the guinea 
pig experiment support a topical than a brain-gut axis methane 
action.
The evidence for rather causative association of methane with 
delayed intestinal motility was further augmented by an elegant 
experiment that aimed to further explore possible effects of gases 
produced in the intestine in the ileum and colon motility. 
Investigators showed in an ex vivo experiment using guinea pig 
ileal, right and left colon segments in a peristaltic tissue bath that: 
(1) ileal contractile activity significantly decreased and the ampli-
tude of peristaltic contractions increased when methane was 
pumped in the bath, while the opposite phenomenon was de-
tected after H2 infusion; (2) colonic transit was shortened by hy-
drogen infusion, but this effect was diminished when methane 
was additionally pumped; these effects being more prominent in 
the right colon.49
Although there are limitations in animal and gas perfusion 
studies to mimic the physiological status of the intestinal environ-
ment, these two translational studies provide experimental evi-
dence to support a direct action of methane to delay intestinal 
transit time.
Intestinal transit time is a physiological marker of intestinal 
motility. It can be measured by different ways, e.g., stool fre-
quency, whole gut, orocecal and colonic transit time etc., with the 
implementation of simple or very sophisticated investigations.50 
Due to these differences, it is very difficult to combine the results 
of these studies. Table 3 summarizes seven adult30,31,51-55 studies 
that included 171 and 287 methane producers and non-pro-
ducers, respectively. There is a clear association of methane pro-
duction and slow intestinal transit, irrespective of health status 
(healthy, IBS or constipated individuals) and of the method used 
Methanogens, Methane and Gastrointestinal Motility
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Table 3. Methane Production and Gastrointestinal Transit (Modified from Kunkel et al46)
Study Condition studied Measurement of transit MP/MnP (n) MP transit MnP transit P
Cloarec et al30 (1990) Healthy adults Orocecal transit time (min) 40/25 111 ± 52 68 ± 24 P  0.005
Levitt et al31 (2006) Healthy adults Stool frequency (bm/day) 78/134 1.03 ± 0.08 1.11 ± 0.06 NS
Chatterjee et al51 (2007) IBS adults Stool frequency (bm/day) 20/67 1.17 ± 0.86 1.96 ± 1.40 P < 0.05
Rumessen et al52 (1994) Healthy adults Orocecal transit time (min) 7/7 75 60 NS
Stephen et al53 (1986) Healthy adults Whole gut transit time (hr) 9/21 84.6 ± 11.7 48.6 ± 6.6 P  0.05
Oufir et al54 (1996) Healthy adults Whole gut transit time (hr) 4/4 95.5 50 P  0.05
Morken et al55 (2007) IBS-like adults Whole gut transit time (hr) 13/29 141 ± 14 95 ± 8 P  0.005
MP, methane producers; MnP, methane non-producers; bm, bowel movements. 
to assess transit in all of them. Even in the two studies31,52 in 
which statistical significance was not reached, a numerical differ-
ence was detected.  
There are two more studies that due to different estimation of 
intestinal motility-using the motility index48,56-are not included in 
the Table 3. Both studies showed that methane breath test pos-
itivity was related to higher fasting motility index, while the study 
of Pimentel et al48 showed a higher postprandial motility index in 
methane producing subjects, as well. Finally, there are 2 stud-
ies57,58 revealing that the prevalence of methane producers was 
higher in the slow transit (75% and 58.8%) compared to the nor-
mal transit (44% and 12.2%) chronic constipated patients and to 
the healthy controls (28% and 13.3%), respectively. Therefore, 
data universally support that production of methane as de-
termined by breath testing, is associated with delayed intestinal 
transit. However, the mechanisms of transit delay induced by 
methane are still unclear. A small study that evaluated 18 Rome I 
IBS patients (4 methane producers) showed that the postprandial 
serotonin level in methane producing patients was lower than in 
hydrogen producers, implicating methane to serotonin pro-
duction for the regulation of intestinal motility.59 
Irritable Bowel Syndrome
IBS is the most common functional disorder characterized by 
the presence of abdominal pain and altered bowel habits. Based 
on the predominant symptom, IBS is broadly divided to con-
stipation predominant (C-IBS) and diarrhea predominant 
(D-IBS) syndrome, and evidence is accumulating for a strong as-
sociation between intestinal methane production and C-IBS.4,5
Overall, the prevalence of methane producers among IBS 
sufferers varies. It ranges from low (14.5% to 15%)60,61 to higher 
(23.8% to 34.4%).62,63 Reasons to explain these differences may 
include among others, varied definitions of IBS status, different 
mix of the 2 main subtypes of the syndrome, controls “contami-
nation” with quiescent IBS or IBS-like symptoms as well as vari-
ability in the detection of methane and in the definition of the 
methane producer and ethnic differences. Table 4 summarizes 
studies supporting an association of methane and constipation re-
lated disorders: C-IBS and chronic constipation. As early as in 
2003, it was shown that a breath test with detectable methane 
could discriminate constipation and diarrheal diseases: a positive 
methane lactulose breath test showed 100% association with 
C-IBS patients while the gas was almost nonexistent in the pre-
dominantly diarrheal conditions of inflammatory bowel diseases.32 
Moreover, subjectively assessed constipation and diarrhea se-
verity scores were higher in methane and hydrogen producers, 
respectively.32 The relationship between constipation and meth-
ane production was also proved in a more detailed nested study 
that assessed constipation severity using both subjective (patients 
perception) and objective (number of bowel movements and 
Bristol stool score) measures in 87 Rome I IBS patients.51 In this 
study, constipation severity was significantly related to methane 
producer status and to the quantity of methane production during 
the lactulose breath testing, whereas methane production was cor-
related to a lower number of bowel movements and Bristol stool 
score. Furthermore, a study that assessed among many other pa-
rameters, stool frequency and consistency, showed that Rome II 
IBS methane predominant producers on sucrose breath testing 
reported more often less than three defecation per week and hard 
or lumpy stools compared to hydrogen producers.56 In a study 
evaluating SIBO in 204 Rome II IBS patients, there were more 
methane producers in C-IBS than in D-IBS group (58% vs. 
28%) while D-IBS had more hydrogen producers (71% vs. 42%) 
during the glucose breath testing.63 Finally, among Rome II IBS 
subjects with bloating and flatulence as predominant symptoms, 
logistic regression analysis revealed that methane was the main 
intestinal gas detected in C-IBS patients (OR, 8; 95% CI, 
1.3-44.0), using glucose breath testing.64 The results of these 
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Criterion for the association
Peled et al62 (1987) IBS 32/11 Association with symptoms
Pimentel et al32 (2003) IBS Lactulose 296/50 Severity of constipation; 100% association with C-IBS
Pimentel et al68 (2003) IBS Lactulose 65/12 Severity of constipation; 100% association with C-IBS
Pimentel et al73 (2006) C-IBS Lactulose 39/12 Therapeutic criterion
Chatterjee et al51 (2007) IBS Lactulose 87/20 Severity of constipation; stool frequency and consistency
Majewski and McCallum63 (2007) IBS Glucose 204/32 Clinical association with C-IBS
Bratten et al61 (2008) IBS Lactulose 224/44 Association with constipation
Grover et al56 (2008) IBS Sucrose 158/10 Association with C-IBS; correlation with the motility index;
  relation to stool consistency
Hwang et al33 (2010) IBS Lactulose 56/28 Methane predicts C-IBS with high sensitivity and specificity 
Attaluri et al57 (2010) CC Glucose 202/87 Correlation with transit time
Reddymasu et al64 (2010) IBS Glucose 98/NM Association with C-IBS
Low et al74 (2010) IBS Lactulose 74/74 Therapeutic criterion
Furnari et al76 (2012) IBS and CC Glucose 629/203 Relation to constipation overall; higher methane excretion (ppm)
  in CC compared to C-IBS patients
Lee et al58 (2013) Constipation Lactulose 62/16 Correlation with transit time
IBS, irritable bowel syndrome; C-IBS, constipation IBS; CC, chronic constipation; NM, not mentioned in the paper; ppm, parts per million. 
studies were recently challenged by a study that failed to detect 
any association between IBS symptoms and methane positivity on 
lactulose breath testing in 68 IBS patients fulfilling the Rome III 
criteria (34% C-IBS).65 Mean symptom severity scores using a 
visual analogue scale for constipation and diarrhea were not re-
lated to methane producer status. However, investigators re-
vealed a weak association between methane positivity and bloat-
ing, flatulence and abdominal pain. To the best of our knowledge 
so far, this is the only study that has not revealed an association 
between methane breath test positivity and constipation in IBS. 
However, the authors acknowledge that the study design in-
corporated a broad subjective definition of constipation without 
measuring stool frequency and consistency which might be re-
sponsible for the discrepant results.65
Since there is no a specific examination, not even a surrogate 
marker, for the diagnosis of IBS, this diagnosis of the syndrome 
is symptom based, as proposed by the Rome Foundation.66 How-
ever, methane detected in a breath testing is a candidate bio-
marker for constipation associated disorders. Indeed, a pro-
spective, double blind, head to head comparison of methane pos-
itivity in lactulose breath test and Rome I IBS classification 
showed that methane positivity had a sensitivity of 91.7% and a 
specificity of 81.3% to correctly assign subjects to the C-IBS 
group.33 Furthermore, a meta-analysis of nine studies that exam-
ined 1,277 individuals found a significant association between 
methane positivity in breath testing and constipation associated 
disorders (OR, 3.51; 95% CI, 2.0-6.16). More importantly, the 
association remained significant (OR, 3.60; 95% CI, 1.84-6.54) 
when only IBS studies were examined.46 These 2 aforementioned 
studies indicate that methane could potentially become a bio-
marker for constipation associated bowel diseases. However be-
fore adopting a diagnostic strategy like that, we must have in 
mind that methane is present in a certain proportion in healthy in-
dividuals, methane does not account for all constipation, there are 
constipated and C-IBS patients without production of methane in 
the breath test and therefore, methane cannot be considered the 
exclusive cause of the symptoms.46
Beyond constipation or diarrhea, IBS is a “constellation” of 
symptoms rather than a single predominant symptom.67 A so-
phisticated factor analysis was conducted in order to explore the 
relationship between various gastrointestinal symptoms and the 
presence of methane in Rome I IBS subjects. Patients answered a 
31 item questionnaire on the severity of their gastrointestinal 
symptoms and underwent a lactulose breath test. The study 
showed that IBS methane producers have a different set of symp-
toms (constipation, small bowel movements, straining, lack of 
milk intolerance and lack of weight loss) as compared to non-pro-
ducers (diarrhea, pain during and after defecation, large and foul 
smelling stool, urgency and weakness after the defecation) pro-
posing again a biomarker role for IBS in order to provide patients 
Methanogens, Methane and Gastrointestinal Motility
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treatment beyond laxatives for constipation.67
A further step toward the clarification of methane’s role in 
IBS was made by identifying the incidence and type of metha-
nogens in C-IBS patients. In a study that included nine Rome II 
C-IBS methane producers and 10 IBS non-methane subjects, 
quantitative PCR revealed that M. smithii was the predominant 
methanogen in all IBS patients. However, absolute counts and 
relative to other stool bacteria proportion of the archaeon were 
significantly higher in methane positive patients. Furthermore, 
the quantity of M. smithii was proportional to the amount of meth-
ane excreted in breath, raising the question of whether M. smithii 
PCR stool testing would be more sensitive than breath methane 
for the diagnosis of C-IBS and for the identification of a sub-
group of C-IBS who would benefit from antibiotic treatment.47
Antibiotic treatment of IBS with poorly absorbable anti-
biotics has gained scientific attention during the last decade. 
After the original trial with neomycin,68 three fully-published and 
one in abstract form, double blind, placebo controlled trials of ri-
faximin69-72 suggest an improvement in IBS symptoms related to 
SIBO eradication.
In a sub-analysis of the neomycin trial,73 there were 12 meth-
ane positive patients among the 111 original study participants 
and all of them belonged to C-IBS group. Neomycin treatment in 
methane producers (n = 5) resulted in significant improvement 
of constipation compared to placebo, concluding that the anti-
biotic use benefit in C-IBS patients is dependent on methane on 
breath testing.
In further work, the same group performed a retrospective 
analysis of treatment data among C-IBS patients.74 In all methane 
positive patients, the treatment of choice was neomycin, rifaximin 
and the combination of the 2 medications before 2004, between 
2004 to 2007 and after 2007, respectively. Data showed that the 
combination of the 2 drugs was most effective in inducing clinical 
improvement and in eliminating methane for methane producers 
(85% and 87%, respectively). 
These 2 treatment studies, although they have certain limi-
tation regarding design, clinical outcome definition and small 
number of included patients, provide further evidence for the use 
of breath test methane positivity as a biomarker to identify C-IBS 
patients that may benefit from antibiotic treatment. Moreover, 
this biomarker can provide objective monitoring of the treatment 
effect, since the clinical response correlates with methane elimi-
nation.73,74
Chronic Constipation
Chronic constipation is another bowel functional disorder 
which is broadly divided into normal and slow transit con-
stipation and in evacuation disorders.66 According to Rome III, 
functional constipation and C-IBS are different entities, however 
the results of a recent provocative study indicate that they are not 
distinct disorders, but rather lie in the spectrum of visceral sensi-
tivity which is modulated by serotonin.75
The relation of methane production and functional con-
stipation has also been examined, albeit less than in IBS. In a 
study of 96 Rome III chronic constipation patients and 106 con-
trols, symptoms were evaluated using questionnaire, methane 
positivity was examined using glucose breath testing and colon 
transit time was measured using radiopaque markers. Methane 
positivity was detected in 75%, 44% and 28% of the slow transit 
(ST) patients, normal transit (NT) patients and controls, respec-
tively. Methane production was highest in the ST followed by the 
NT patients and it correlated with colon transit time.57 Surprisin-
gly, methane production was not related to stool frequency or 
consistency in contrast to findings in C-IBS.51
In another retrospective study, 62 Rome III constipated pa-
tients and 49 controls had lactulose breath testing for methane 
production and an accurate colon transit time measurement with 
markers. Investigators showed that breath methane was positive 
in 58.8%, 13.3% and 12.2% in the ST, NT patients and controls, 
respectively.58 Colon transit, and more prominently left colon 
transit time, appeared related to the total production of CH4. 
However, methane positivity was not related with stool consisten-
cy. Furthermore, investigators did not reveal any relationship be-
tween methane production and anorectal manometry findings.58
Using a different approach, the association of CH4 pro-
duction and various functional gastrointestinal symptoms was 
studied prospectively in a set of 629 patients and 40 controls, us-
ing questionnaire symptom assessment and glucose breath test.76 
Methane positivity was similar among patients and controls 
(32.3% and 30%, respectively), however there was significantly 
more methane production in patients (21.1 ppm vs. 6.1 ppm; P 
= 0.045, respectively) than in control. Regression analysis re-
vealed that methane excretion was related only to constipation. 
When constipated patients were divided in those with chronic 
constipation and C-IBS, methane production was higher in the 
chronic constipation patients (30.3 ppm vs. 21.5 ppm; P = 
0.046, respectively) than in C-IBS patients.76
In contrast to C-IBS methane eradication treatment data, 
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there is absence of trials evaluating the effects of antibiotic treat-
ment in methane production and symptom resolution in func-
tional constipation. There is only one case report77 of a patient 
with slow transit constipation and methane positivity (while fast-
ing and after glucose ingestion) whose stool frequency and con-
sistency improved, and colon transit accelerated after 14 days 
treatment with refaximin 400 mg t.i.d. Moreover, glucose breath 
methane excretion 10 days after end of treatment was  5 ppm 
compared to 36 ppm before treatment, indicating that con-
stipation improvement was related to methane eradication.
Gastroparesis
Gastroparesis symptoms include postprandial fullness, early 
satiety, abdominal pain, nausea, vomiting and bloating without 
obstruction. It may be idiopathic or secondary to diabetes melli-
tus, gastric-surgical procedures and  opioid consumption etc.78 
Interestingly, while gastric emptying is delayed, gastroparesis 
symptoms do not correlate well with the degree of the delay as-
sessed by scintigraphy, suggesting that other factors may contrib-
ute to the development of symptoms.79
Although the evidence is still poor to reach firm conclusions, 
we report herein the only two available studies that have evaluated 
methane production in gastroparesis patients. SIBO has been de-
tected by positive glucose methane breath testing in 27% of 50 
gastroparesis patients complaining mainly about abdominal pain 
and bloating.80 In a larger study evaluating 201 patients with 
symptom severity questionnaire, scintigraphic gastric emptying 
measurement and lactulose breath testing, only 6 (3%) patients 
had positive methane breath test (breath methane increase of  
20 ppm above baseline by 90 minutes) and there was no relation 
of methane positivity to gastric emptying time and severity of 
symptoms.81
Conclusions
Methane is a unique gas produced in strict anaerobic con-
ditions by intestinal methanogens that metabolize H2, one of the 
end products of bacterial fermentation. Although thought of as 
an inert gas, there is evidence from translational medicine that 
methane acts like a neuromuscular transmitter resulting in re-
duced propagation of the peristaltic movement in the intestine. 
This evidence is further supported by the universal finding in 
physiological studies that CH4 production (measured by breath 
testing) delays transit time and by clinical studies showing a rela-
tionship between methane status on breath testing with delayed 
transit associated conditions like constipation predominant IBS 
and chronic constipation. There is also preliminary evidence that 
antibiotic treatment results in improvement of symptoms in a cer-
tain proportion of patients suffering from these disorders in a 
fashion related to its ability to eradicate methane. However, 
methane is also detected in healthy individuals and all con-
stipation patients and symptoms are not associated with high 
methane production, meaning that there is plenty of room for re-
search to identify the mechanism of action of methane on in-
testinal motility before recommending methane as a biomarker 
for the diagnosis of constipation related disorders or as a bio-
marker for selecting patients who may benefit from antibiotic 
eradication of methane.  
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